Advances in pharmacogenomic research and development.
Technological achievements in the last 5 to 10 yr and their application to sequencing and polymorphism discovery in the human genome have fostered a renewed interest in the genetic basis of drug response. Consequently, the field of pharmacogenetics/pharmacogenomics has been gaining momentum, fueled not only on technology but also on results of empirical studies of the human genome and on genetic epidemiology studies of real drugs in patient populations. This review discusses some of the recent advances in pharmacogenomic research and development over the last few years that include understanding the architecture of the human genome, the creation of population deoxyribonucleic acid (DNA)/data banks, assessment of the clinical validity of genetic markers, and experience with regulatory aspects of pharmacogenomics.
McCarthy
Jeanette J
JJ
San Diego State University, 5500 Campanile Dr., San Diego, CA 92182-4162, USA.
D005819:Genetic Markers; D015894:Genome, Human; D006801:Humans; D015810:Linkage Disequilibrium; D010597:Pharmacogenetics / Q000592:standards / Q000639:trends; D020641:Polymorphism, Single Nucleotide; D012106:Research; D013678:Technology, Pharmaceutical
D005819:Genetic Markers